Neumora Therapeutics Statistics
Total Valuation
NMRA has a market cap or net worth of $370.94 million. The enterprise value is $219.50 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NMRA has 167.09 million shares outstanding. The number of shares has increased by 2.49% in one year.
| Current Share Class | 167.09M |
| Shares Outstanding | 167.09M |
| Shares Change (YoY) | +2.49% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 4.91% |
| Owned by Institutions (%) | 31.03% |
| Float | 89.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.72 |
| P/TBV Ratio | 2.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.85, with a Debt / Equity ratio of 0.15.
| Current Ratio | 6.85 |
| Quick Ratio | 6.64 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -203.38 |
Financial Efficiency
Return on equity (ROE) is -104.35% and return on invested capital (ROIC) is -63.22%.
| Return on Equity (ROE) | -104.35% |
| Return on Assets (ROA) | -56.71% |
| Return on Invested Capital (ROIC) | -63.22% |
| Return on Capital Employed (ROCE) | -158.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.15M |
| Employee Count | 110 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NMRA has paid $130,000 in taxes.
| Income Tax | 130,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.28% in the last 52 weeks. The beta is 3.16, so NMRA's price volatility has been higher than the market average.
| Beta (5Y) | 3.16 |
| 52-Week Price Change | -77.28% |
| 50-Day Moving Average | 2.27 |
| 200-Day Moving Average | 1.47 |
| Relative Strength Index (RSI) | 44.32 |
| Average Volume (20 Days) | 1,140,160 |
Short Selling Information
The latest short interest is 6.10 million, so 3.65% of the outstanding shares have been sold short.
| Short Interest | 6.10M |
| Short Previous Month | 6.54M |
| Short % of Shares Out | 3.65% |
| Short % of Float | 6.80% |
| Short Ratio (days to cover) | 2.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -240.60M |
| Pretax Income | -236.17M |
| Net Income | -236.30M |
| EBITDA | -240.24M |
| EBIT | -240.60M |
| Earnings Per Share (EPS) | -$1.46 |
Full Income Statement Balance Sheet
The company has $171.53 million in cash and $20.09 million in debt, giving a net cash position of $151.44 million or $0.91 per share.
| Cash & Cash Equivalents | 171.53M |
| Total Debt | 20.09M |
| Net Cash | 151.44M |
| Net Cash Per Share | $0.91 |
| Equity (Book Value) | 132.16M |
| Book Value Per Share | 0.82 |
| Working Capital | 151.24M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$208.83 million and capital expenditures $759,000, giving a free cash flow of -$208.07 million.
| Operating Cash Flow | -208.83M |
| Capital Expenditures | 759,000 |
| Free Cash Flow | -208.07M |
| FCF Per Share | -$1.25 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |